# Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women

> **NCT00102141** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 750 (actual)

## Conditions studied

- Hypertension
- Postmenopause

## Interventions

- **DRUG:** Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
- **DRUG:** Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
- **DRUG:** Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
- **DRUG:** Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00102141
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 750 (ACTUAL)
- **Last updated:** 2014-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102141, "Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00102141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*